galactosamine has been researched along with pyrazolanthrone in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Aoyagi, Y; Honda, Y; Ichida, T; Matsuda, Y; Suzuki, K; Takamura, M; Tamura, Y; Yamagiwa, S | 1 |
Galle, PR; He, YW; Kohl, T; Kreft, A; Nagel, M; Schattenberg, JM; Schuchmann, M; Schulze Bergkamen, H; Siebler, J; Sprinzl, MF; Wörns, M; Zimmermann, T | 1 |
2 other study(ies) available for galactosamine and pyrazolanthrone
Article | Year |
---|---|
An inhibitor of c-Jun NH2-terminal kinase, SP600125, protects mice from D-galactosamine/lipopolysaccharide-induced hepatic failure by modulating BH3-only proteins.
Topics: Alanine Transaminase; Animals; Anthracenes; Apoptosis; Aspartate Aminotransferases; bcl-Associated Death Protein; BH3 Interacting Domain Death Agonist Protein; Disease Models, Animal; Down-Regulation; Drug Therapy, Combination; Enzyme Inhibitors; Galactosamine; Hepatocytes; Injections, Intraperitoneal; Injections, Subcutaneous; JNK Mitogen-Activated Protein Kinases; Lipopolysaccharides; Liver Failure; Longevity; Male; Mice; Mice, Inbred BALB C; Peptide Fragments; Proto-Oncogene Proteins | 2007 |
Ablation of c-FLIP in hepatocytes enhances death-receptor mediated apoptosis and toxic liver injury in vivo.
Topics: Animals; Anthracenes; Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspases; Chemical and Drug Induced Liver Injury; Concanavalin A; fas Receptor; Female; Galactosamine; Hepatocytes; Lipopolysaccharides; MAP Kinase Signaling System; Mice; Mice, Knockout; Receptors, Death Domain | 2011 |